74
Participants
Start Date
June 8, 2020
Primary Completion Date
July 3, 2023
Study Completion Date
July 3, 2023
Selinexor
Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
Temozolomide (TMZ)
Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
Lomustine (CCNU)
Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
Standard Fractionated Radiation therapy (RT)
Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
Bevacizumab
Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
TTField
Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
Carmustine
Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous
Columbia University Irving Medical Center, New York
Lenox Hill Hospital-Northwell Health, New York
Northwell Health, Lake Success
Piedmont Healthcare, Atlanta
Baptist Hospital of Miami Cancer Institute, 8900 North Kendall Drive, Miami
University of Alabama, Birmingham
Cleveland Clinic, Cleveland
Northwestern University Feinberg School of Medicine, Chicago
MD Anderson Cancer Center, Houston
University of Utah - Huntsman Cancer Institute, Salt Lake City
University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center), Los Angeles
University of California, San Francisco
University of Washington - Alvord Brain Tumor Center, Seattle
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Hackensack Meridian Health, 92 Second Street, Hackensack
Atlantic Health Systems Hospital Corp., Morristown
Princess Margaret Hospital (PMH), Toronto
Lead Sponsor
Karyopharm Therapeutics Inc
INDUSTRY